Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorrene A Buckley

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Protocols in Toxicology|October 10, 2012
Toxicology testing in drug discovery and developmentMichael A Dorato, Lorrene A Buckley
Regulatory Toxicology and Pharmacology : RTP|May 30, 2009
High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspectiveLorrene A Buckley, Michael A Dorato
Current Protocols in Pharmacology|February 2, 2012
Toxicology in the drug discovery and development processMichael A Dorato, Lorrene A Buckley
International Journal of Toxicology|July 14, 2023
Pharmaceutical Industry Perspective on the Non-Clinical Evaluation of Novel Excipients: Results From an Industry Survey Conducted by the IQ Novel Excipient Working GroupPaul S Giffen, Lorrene A Buckley, Jason Pinkstaff
International Journal of Pharmaceutics|July 22, 2017
Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipientsLorrene A Buckley, Smita Salunke, Karen Thompson, et al.
Regulatory Toxicology and Pharmacology : RTP|December 22, 2018
Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership GroupJoanne Birkebak, Lorrene A Buckley, Donna Dambach, et al.
Regulatory Toxicology and Pharmacology : RTP|July 5, 2024
Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetineRobert A Jolly, Paul D Cornwell, Jessica Noteboom, et al.
International Journal of Toxicology|June 14, 2012
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agentLorrene A Buckley, Atsushi Sanbuissho, James J Starling, et al.
International Journal of Toxicology|August 9, 2020
Drug Development 101: A PrimerLorrene A Buckley, Ilona Bebenek, Paul D Cornwell, et al.
International Journal of Toxicology|October 21, 2011
Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticalsLorrene A Buckley, Kathryn Chapman, Leigh Ann Burns-Naas, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Protocols in Toxicology|October 10, 2012
Toxicology testing in drug discovery and developmentMichael A Dorato, Lorrene A Buckley
Regulatory Toxicology and Pharmacology : RTP|May 30, 2009
High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspectiveLorrene A Buckley, Michael A Dorato
Current Protocols in Pharmacology|February 2, 2012
Toxicology in the drug discovery and development processMichael A Dorato, Lorrene A Buckley
International Journal of Toxicology|July 14, 2023
Pharmaceutical Industry Perspective on the Non-Clinical Evaluation of Novel Excipients: Results From an Industry Survey Conducted by the IQ Novel Excipient Working GroupPaul S Giffen, Lorrene A Buckley, Jason Pinkstaff
International Journal of Pharmaceutics|July 22, 2017
Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipientsLorrene A Buckley, Smita Salunke, Karen Thompson, et al.
Regulatory Toxicology and Pharmacology : RTP|December 22, 2018
Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership GroupJoanne Birkebak, Lorrene A Buckley, Donna Dambach, et al.
Regulatory Toxicology and Pharmacology : RTP|July 5, 2024
Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetineRobert A Jolly, Paul D Cornwell, Jessica Noteboom, et al.
International Journal of Toxicology|June 14, 2012
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agentLorrene A Buckley, Atsushi Sanbuissho, James J Starling, et al.
International Journal of Toxicology|August 9, 2020
Drug Development 101: A PrimerLorrene A Buckley, Ilona Bebenek, Paul D Cornwell, et al.
International Journal of Toxicology|October 21, 2011
Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticalsLorrene A Buckley, Kathryn Chapman, Leigh Ann Burns-Naas, et al.
Pageof 2